Phase Space AI

Valuation and Trade

Natera [NTRA]

Natera [NTRA] — Valuation, Criteria Scorecard, Trade Construction & Catalysts

Phase Space Research | original 2026-07-27 · methodology update 2026-07-29 | framework v1.7.0 (Criteria ruleset, references/criteria.md 2026-07-29) | Price at update $251.98 (2026-07-28 close) | EV $35.0bn

This memo no longer issues a position verdict. It scores Criteria and produces two valuation outputs. Whether the analysis justifies a position is a question about a particular book, and two books answer it differently. Sections below that were written under the retired "Gate / E[R] vs cash hurdle" ruleset are marked SUPERSEDED where their conclusions no longer stand. Their evidence is retained deliberately.

---

0. Methodology update — 2026-07-29. What changed, and why the answer moved

0.1 The old conclusion, and the defect that produced it

The 2026-07-27 memo concluded "WATCHLIST — no position; probability-weighted value $129.26 against a $258.03 spot; scenario-weighted E[R] −49.9% (range −80.9% to −5.3%) against a +4.7% cash hurdle." That number was an artifact of two specific errors, both now fixed:

1. The exit multiple was drawn from a comparator set with no growth dispersion. The anchors were a listed diagnostics/tools peer median (~7.5x sales) and the Abbott/Exact precedent (~7.0x) — a set spanning 1.0–7.5% revenue growth (ILMN 1%, QGEN 3%, BRKR 2%, DGX 7.5%, LH 7.0%) applied to a company compounding at 41%. A growth/multiple slope cannot be estimated from a sample with no growth dispersion, and this one was then extrapolated roughly 5x beyond its support. The memo then set base at 5.0x — below both of its own stated anchors, a distant-year haircut stacked on a multiple that had already fully mean-reverted. That double-counts conservatism, and it was applied silently.
2. The sensitivity was run on the parameter that could not change the answer. §3.2 ranged over scenario probabilities, stated that "there is no assignment of probabilities across these three scenarios that produces a positive expected return", and then conceded the flip point "has to be sought on the exit multiple, which is where the real judgement lives." The memo diagnosed its own defect and did not act on it. Sensitivity now runs over the exit multiple.

0.2 Inputs — pre-computed, and the two corrections made to them

Inputs come from the pre-computed cross-sectional scan at reports/scan/NTRA_analysis.json (as-of 2026-07-28) rather than being recomputed here. Two of its fields are wrong and are corrected below, with the correction stated rather than silently applied (spec item 6):

Resulting EV: $34,999m = 14.0x TTM revenue (the scan's uncorrected pair gives 15.4x).

0.3 The implied-path test (reverse DCF) — the Valuation Criteria

assets/reverse_dcf.py, solving for revenue CAGR. Held fixed: terminal EBIT margin 20.0%, exit multiple 53.4x EBIT, WACC 10.0%, horizon 5 years, EV $34,999m, revenue base $2,500.9m.

What the price requires: a 16.1% five-year revenue CAGR.

What Natera has demonstrated: 41.1%.

MARGIN = demonstrated − required = +25.0 percentage points. Valuation Criteria: PASS.

The exit multiple and its compression, as a number. 53.4x EBIT at a 20% terminal margin is 10.68x exit-year sales, against 14.00x trading today — the path already embeds a −23.7% multiple compression. The multiple's basis is GROWTH_MATCHED: the qualifying comparators are the five names in the scan universe whose growth brackets Natera's 41.1% within ±50% — NOW (22.4%, 57.4x), AVGO (24.4%, 64.1x), FSLR (25.8%, 13.7x), ANET (27.1%, 53.4x), GMED (42.2%, 22.0x). Disclosed weakness: n=5 is the minimum the rule permits, only one comparator sits above the subject's growth, and the set is growth-matched but NOT sector-matched. That is a genuine limitation and it is stated rather than buried — but it is a far better identified set than the 1.0–7.5% growers the old memo used, which could not identify the slope at all.

0.4 Sensitivity — over the exit multiple, never over scenario probabilities

Break-even exit multiple — the number the old memo should have solved for. Holding the demonstrated 41.1% CAGR, today's price is justified all the way down to a 20.1x EBIT / 4.03x sales exit. The old memo's base assumption was 5.0x sales. On the corrected revenue and net-cash figures, even the old memo's own 5.0x assumption clears the bar. The −49.9% E[R] did not come from the multiple being 5.0x; it came from asserting a revenue path (18.0% base) far below what the business demonstrates, and then valuing that path at 5.0x.

Second sensitivity, on the other unargued parameter. Holding 41.1% growth and 53.4x, the break-even terminal EBIT margin is 7.5% — below Natera's own FY2025 gross-margin structure would imply and far below the 20% assumed. The Valuation Criteria result is not resting on the margin assumption either.

0.5 Caveat on the terminal margin — stated because it is the largest unargued input

The scan does not persist terminal_margin. Back-solving from its published required_cagr_pct returns exactly 0.2000 for NTRA, GH and TWST alike — i.e. the run used a flat 20% for every name, not the per-name sector-derived figure the current coverage_scan.py produces. A 20% terminal EBIT margin for a company that has never been profitable is an assumption, not a measurement. It is disclosed here, and §0.4's break-even (7.5%) is the answer to how much it matters: for NTRA, not much.

0.6 The 12-month target (mandatory alongside the implied path — different horizon, different instrument)

Built per references/valuation.md: near-term consensus revenue, multiple anchored on Natera's own trading history and percentile, never a peer median projected forward.

• Revenue base: TTM $2,500.9m grown at the Street's own implied FY2026 growth (+21.3%: consensus FY2026E $2,797m, 21 analysts, Alpha Vantage cached 2026-07-27, vs FY2025 actual $2,306.1m) → NTM $3,033m. Cross-check: a direct 5/12 FY2026E + 7/12 FY2027E ($3,328m) blend gives $3,107m, 2.4% higher. The lower figure is used.
• Multiple anchor — Natera's own EV/Sales history, 2022-07-01 to 2026-07-28 (1,021 trading days, EV rebuilt daily from the then-current share count and then-reported TTM revenue): today 13.84x = the 93rd percentile of the four-year range (min 2.87x, median 9.73x, upper quartile 11.47x, max 15.97x). Against the trailing twelve months only, 13.84x is the 71st percentile (1y median 12.02x).

Base is the trailing-1-year median, not the 4-year median, because the four-year window spans a pre-Signatera- reimbursement regime the company has structurally left (seven Medicare-covered indications, gross margin 41%→~65%); reverting to it would be reverting to a different business. The choice is stated because it drives the answer.

Named 12-month product-cycle events feeding it (all already dated in §4): Q2-2026 earnings ~6 Aug 2026; the CY2027 ADLT re-determination in Q4 2026; FY2027 guidance ~Feb 2027. No undated or unsourced catalyst is used.

Sanity band against external targets. Street average ~$282 (+9.3%). The external healthcare specialist whose book is held out as a reference (snapshot 2026-07-28, reports/critique/his-actual-framework-2026-07-28.md) carries NTRA long at a +5% expected return — within 1 percentage point of this base target. That is a check on the output, never a calibration target for the model.

0.7 Criteria scorecard (Gates retired 2026-07-29)

Archetype: INFLECTION (negative operating margin, high gross margin, terminal-weighted value).

0.8 What moved, in one line

Old: worth $119 (base) / $129 (probability-weighted) against a $252–258 spot; E[R] −49.9%; WATCHLIST. New: the price requires a 16.1% revenue CAGR against 41.1% demonstrated — a +25.0pp margin, PASS — and a 12-month base target of $262 (+4.0%). Why it moved: the exit multiple is now drawn from comparators that actually bracket Natera's growth (53.4x EBIT ≈ 10.7x sales, versus 5.0x sales pulled from 1–7.5% growers); the question changed from "assert a path, assert a multiple, report an expected return" to "solve for what the price requires and test it against what the business has done"; and TTM revenue and net cash were corrected (+6.5% and +$904m respectively). The direction of the move is almost entirely the anchoring fix.

---

1. Valuation (SUPERSEDED as to conclusions — retained as evidence)

1.1 DCF — reported, and deliberately down-weighted

Why ten years and why it is down-weighted. Natera's unlevered FCF does not turn positive until FY2029E; a five-year window would terminate in a loss-making year and capitalise a negative cash flow. Extending to FY2035E gives a normalised terminal year — but terminal value is still 85.4% of EV, so this DCF capitalises an assumption, not an observation. Per the SMR and GH precedents, for a company that is not durably profitable the DCF is the wrong primary tool. FY2025 operating loss was $310m and operating cash flow excluding the SBC add-back was −$139m. The scenario framework below carries the weight; the DCF is a cross-check only.

Sensitivity — every cell is far below spot ($258.03):

(The grid fully re-discounts every forecast-year cash flow and the terminal value at each row's WACC. The base cell reads $43 against the model's $40.40 headline because the grid re-solves off a rounded UFCF vector and a 140.5m share count rather than scaling the model output.)

1.2 Scenario framework — this carries the weight

Valued on FY2030E revenue at an anchored exit EV/Sales, discounted back 4.5 years at 10.54%.

SUPERSEDED (2026-07-29). Probability-weighted value $129.26 · Scenario-weighted E[R] −49.9% · versus a 4.7% cash hurdle, a shortfall of −54.6 percentage points. This output is retired. The cash hurdle no longer exists in the framework, and the exit multiples below (3.0x / 5.0x / 7.5x) were anchored on a 1.0–7.5% growth peer set and applied to a 41% grower — the defect §0.1 describes. The scenario table itself is kept because the unit and ASP build is real work; its valuation conclusion is not. See §0.3 for the replacement.

Where the exit multiples come from — anchored, not picked. Base 5.0x rests on two real anchors: Abbott paid ~7.0x sales in cash for Exact Sciences (closed 23 March 2026), and the listed diagnostics/tools peer median is ~7.5x today. Applying 5.0x to a year five years out sits below both, which is the right direction of travel for a distant year. The Bull case at 7.5x is today's peer median applied five years forward.

Robustness — this is what makes the conclusion usable. Holding base FY2030E revenue at $5.29bn: $96 at 4.0x · $119 at 5.0x · $164 at 7.0x (the Abbott precedent) · $175 at 7.5x (today's peer median). Even at today's peer median applied five years forward, on the base revenue path, the stock is 32% overvalued.

1.3 Comparables

NTRA at 14.3x is roughly 2x the peer median and 2x the price a strategic just paid in cash for the category incumbent — though it is also growing far faster than any peer except GH, and that is a real defence.

1.4 Consensus bridge (required)

Decomposing the disagreement — is it numbers or multiple? It is entirely the multiple, and this is provable. On revenue the house is 3.9% above the Street for FY2026E and 2.3% above for FY2027E. The house is more bullish on the numbers, and still lands 54% below the Street's target. The entire gap is the exit multiple applied to a broadly agreed revenue path: the Street is implicitly capitalising FY2030E revenue at roughly 11–12x; the house uses 5.0x, anchored on a cash takeover at ~7x and a peer median at ~7.5x.

Note the direction, because it matters for the gates: a house number above consensus is a variant that argues for a long, not a short. There is no negative variant here at all.

Why the house is above the Street on FY2026E. Natera has raised guidance in five consecutive quarters (2025 by $80m at Q2, $160m at Q3; 2026 by $120m at Q1). Q1-2026 printed +38.8% y/y, whereas consensus FY2026E of $2,797m requires only +16.4% across Q2–Q4. The serial-raise pattern makes a modest beat the base case.

The real risk if the Street is right: Natera is the evidence and coverage leader in a category (ctDNA-guided therapy) whose literature is compounding faster than anything else in diagnostics, with seven Medicare-covered indications, a fresh NCCN bladder recommendation naming its technology, a debt-free balance sheet and $1.09bn of cash. Category leaders in reimbursement inflections have historically sustained multiples that look indefensible on a spreadsheet for years — and get acquired at premiums to them. That is a genuine argument and it is why this is a Watchlist and not a Short.

---

2. Factor & Anomaly Scorecard

Universe percentiles computed from a reconstructed liquid US universe (7,230 symbols pulled; 2,117–4,036 pass the liquidity filters), Alpaca SIP monthly bars.

Momentum is entry timing, not selection (2026-07-29). The 12-1 figure above (+103.1%, "top 11.2%") was computed on 2026-07-27 against a reconstructed universe; the current cross-sectional scan puts NTRA at +97.2%, 79.7th percentile (6-1 +13.3%, 57.1st; RSI-14 33.1). Momentum Criteria is MEASURED. It governs when to enter a position the thesis already justifies, never whether to own it. Every clause below and in §2.1 that treats a momentum decile as a reason to own or not own a name is retired. RSI-14 at 33.1 inside a strongly positive 12-month trend is a timing observation and nothing more.

Synthesis. Six of the seven fundamental/technical anomaly signals favour ownership, and the one that does not (asset growth) is mechanically inflated by an acquisition. Momentum is positive, accruals are clean, gross profitability is high, and revisions are rising — this is close to the textbook profile of a bad short, and it is essentially the GH conclusion again. The bear case here is a valuation case, and the scorecard says so plainly.

2.1 Screen provenance — NTRA genuinely did not clear, and here is what that means

The brief states NTRA did not appear on the 2026-07-27 screen, failing the top-8% momentum shortlists in either direction. Unlike the GH case — where the "did not clear" framing turned out to be wrong — this is correct for NTRA, and I verified it rather than assuming it.

Reconstructing the universe from monthly Alpaca SIP bars: NTRA's 12-1 momentum of +103.1% ranks in the top 11.22% of 4,036 liquid names (top 11.91% at ADV>$2m, 12.61% at >$5m, 13.37% at >$20m). The top-8% threshold was +136.6%. NTRA missed it by roughly 33 percentage points of momentum. The result is robust across every liquidity filter.

(Separately: the screen's shortlists were capped at 75 names per side, which on this tape required +312% momentum to make the long list and −65.6% to make the short list. NTRA would not have made the list under either the stated 8% rule or the cap. The cap issue found on GH is real and remains logged for the screener, but it does not change NTRA's answer.)

What it means, stated plainly because it is base-rate-relevant and not a footnote. Momentum is the most robust anomaly in the empirical record, and NTRA sits in the second decile, not the first. So: - There is no top-decile momentum tailwind to support a long, and the empirical edge from momentum here is real but ordinary — this name does not arrive with the base-rate support that a screened name does. - Equally, NTRA is not a momentum-negative name. At +103.1% over 12-1, 90.9% of its 52-week high and +17.9% above its 200-day, a short would still be fighting a strong tape. "Failed the momentum screen" must not be misread as "momentum is neutral or negative." - Per the skill's own framing (Grinold: IR ≈ IC × √breadth), underwriting an unscreened name is a deliberate departure from the selective-breadth edge hypothesis. It is justified here by the diversification rationale in the brief, but the absence of screen support is itself a mild negative on prior odds, and it is recorded as one.

2.2 Correlation — NTRA vs GH is one bet, not two

Trailing 252-day daily returns vs NTRA:

NTRA–GH: +0.492 (252d), +0.603 (126d), +0.464 (63d). The 126-day figure is above the book's 0.60 pairwise disclosure threshold. Mean correlation to the ten-name AI-infrastructure cluster: +0.167. Versus SPY +0.337, versus XBI +0.491.

Two conclusions, both required by the brief. First, any NTRA + GH pairing is a single factor bet and must be sized as one position — the correlation is computed from actual daily returns and it is the highest in the comparison set. Second, NTRA is a genuine diversifier against the AI-infrastructure complex that dominates the book (+0.167 mean), though materially less so than GH (+0.071). Neither fact can rescue a negative standalone expected return. Diversification scales a positive edge; it cannot manufacture one.

---

3. Trade Construction — the four conclusions, kept separate

1. Fundamental conclusion — POSITIVE. Gross margin 41%→67%; oncology units compounding ~50%+ for eleven quarters; blended ASP +81% in three years and still +19.9% y/y through the first ADLT rate cut; seven Medicare-covered indications; a fresh NCCN bladder recommendation naming Signatera technology; $1.09bn cash and effectively no debt. This is a business executing.
2. Expectations conclusion — FULLY DISCOUNTED, AND THEN SOME. 22 analysts at Buy, target ~$282 above spot, consensus revenue below the house build, EPS revisions rising, stock +103% over twelve months. There is no negative gap. The house is more bullish than the Street on the numbers.
3. Valuation conclusion — RESTATED 2026-07-29. (Was: "NEGATIVE — probability-weighted value $129.26 vs $258.03.") On the implied-path test the price requires a 16.1% five-year revenue CAGR against 41.1% demonstrated: a +25.0pp margin, Valuation Criteria PASS, holding across the full exit-multiple sensitivity. The 12-month base target is $262 (+4.0%). See §0.3–§0.6.
4. Portfolio conclusion — REMOVED. (Was: "NO POSITION.") This memo issues no position verdict. It scores Criteria (§0.7) and produces two valuation outputs (§0.3, §0.6). Whether that justifies a position, at what size and in what vehicle, is a question about a particular book — and the same analysis is answered differently by an absolute-return book and by a risk-normalised one.

3.1 Criteria-by-Criteria (evidence retained; verdicts restated in §0.7)

"Gates" were retired on 2026-07-29. The table below is the original gate block with the names mapped forward. The reasoning column is unaltered — it is the record. Where a verdict changed under the new ruleset, §0.7 is authoritative and the change is stated there.

The binding gate is Gate 4, and it is binding in an unusually strong sense — see below. Gate 2 also fails, on both branches.

3.2 E[R] range and flip point (SUPERSEDED 2026-07-29 — this is the defect, preserved)

Read this section as the exhibit, not the analysis. It ranges over scenario probabilities, concludes that no probability assignment can change the answer, and then says the flip point "has to be sought on the exit multiple, which is where the real judgement lives." That is correct, and the memo did not act on it. The replacement — a sensitivity run over the exit multiple, with a break-even multiple stated — is §0.4. The conclusions below do not stand.

RANGE: −80.9% to −5.3%. The cash hurdle of +4.7% sits ENTIRELY ABOVE the range, not inside it.

The flip point does not exist on the probability weightings. Because the Bull case itself returns −5.3%, there is no assignment of probabilities across these three scenarios that produces a positive expected return, let alone one clearing the hurdle. Even at 100% Bull weight the shortfall is −10.0pp. This is emphatically not a "decision determined by a judgement input" case — reweighting cannot rescue it.

The flip point therefore has to be sought on the exit multiple, which is where the real judgement lives:

FLIP POINT: the exit multiples must rise by 2.15x — to Bear 6.4x / Base 10.7x / Bull 16.1x on FY2030E revenue — for E[R] to reach the 4.7% cash hurdle.

For calibration, spot implies 11.2x FY2030E EV/Sales on the base revenue path ($5.29bn, an 18.0% five-year CAGR), 7.9x on the bull path, and 17.6x on the bear path. So the entire decision reduces to one question: is 10.7x sales, five years forward, on a business at ~5% operating margin, a defensible multiple? Against a ~7.5x peer median and a ~7.0x cash takeover of the category incumbent, I do not think so — but I hold that view with appropriate humility, because it is the only thing standing between this and a long, and it is a judgement about a multiple, not a fact about the business.

This is a FAIL by 54.6 percentage points, not a FAIL by 0.4. Recorded explicitly per C4 so the magnitude is not flattened into the same word used for ISRG (−0.4pp) or NBIS (−1.9pp). Nothing marginal is happening here.

3.3 Analysis summary — no position verdict is issued

POSITION VERDICT: NONE. This memo does not output Long / Short / Watchlist / Avoid.
                  It outputs an analysis. Whether it justifies a position belongs to a book,
                  and an absolute-return book and a risk-normalised book answer it differently.

VALUATION CRITERIA (implied path, 5y):  price requires 16.1% revenue CAGR
                                        demonstrated 41.1%   MARGIN +25.0pp   PASS
   exit multiple 53.4x EBIT = 10.68x exit sales, basis GROWTH_MATCHED (n=5)
   implied compression from 14.00x trading today: -23.7%
   PASS across 0.6x-1.5x of the anchor; break-even exit multiple 20.1x EBIT / 4.03x sales
12-MONTH TARGET: $262 base (+4.0% to $251.98 spot); low $214 (-15.2%); high $301 (+19.3%)
                 multiple anchored on NTRA's OWN EV/Sales history (13.84x = 93rd pctile of 4y,
                 71st pctile of 1y); revenue base NTM $3,033m off Street FY2026E
QUALITY CRITERIA (BINDING): PARTIAL - gross-margin and growth limbs PASS,
                 operating-margin-CHANGE limb FAILS (-0.3pp YoY vs a ~+5pp standard)
LIQUIDITY CRITERIA (BINDING): PASS
MOMENTUM CRITERIA (MEASURED - ENTRY TIMING ONLY, NEVER SELECTION):
                 12-1 +97.2% (79.7th pctile), 6-1 +13.3% (57.1st), RSI-14 33.1 (soft near term)
CATALYST / DOWNSIDE / PEER SPREAD / CONSENSUS / SHORT MECHANISM: see §0.7
INVALIDATION OF THE ANALYSIS (not of a position): the CY2027 ADLT re-determination cutting the
                 Signatera rate AND blended ASP breaking with it - the named permanent-loss mechanism
TIME HORIZON:    Q2-2026 earnings (~6 Aug 2026), then the CY2027 ADLT determination (Q4 2026)
CONSENSUS:       Street Buy, ~22 analysts, average target ~$282 (+9.3%); EPS revisions 7 up / 2 down
                 in 30 days. External reference book: long NTRA at a +5% expected return.

What is deliberately absent. No entry price, no sizing, no vehicle recommendation and no "conviction" tier appear here any more. Those are strategy outputs, not analysis outputs. §3.4's priced option structures are retained as liquidity evidence for the Liquidity Criteria — the chains were pulled live — not as a recommendation.

This is the NET/GH case again, and it is named as such. The trade-construction reference warns that growth names hit the "expensive but not a short" trap repeatedly, and that a rich multiple is more often earned where a genuine regime change is underway. Scored honestly against the regime-change tiers: Natera's advantages are Tier 2 (physical/technical) — an ultrasensitive assay platform with a 70-to-1 publication lead over its nearest tumour-informed competitor — and Tier 3 (structural) — seven Medicare-covered indications and NCCN inclusion. There is no Tier 1 contractual evidence (no take-or-pay, no minimum-volume commitments, and ADLT rates are reset annually by CMS against the company). Per Principle 2, Tier 2 can carry a regime-change conclusion — and I accept that Natera's gross-margin and coverage position is a genuine structural improvement, not a cyclical one. What Tier 2 evidence cannot do is justify 11.2x FY2030E sales. I am skeptical of the multiple. Scored honestly, skepticism about a multiple is not Gate 1 or Gate 2 evidence, and it is not dressed up here as if it were.

3.4 Vehicles priced, and why each was rejected

Alpaca options data pulled live 2026-07-27. Six expirations listed (Aug-21, Sep-18, Oct-16, Nov-20, Dec-18, Jan-15-2027); Aug-21 captures the Q2 print.

Variance risk premium check (required before any naked premium). ATM October IV is ~55% against 43.8% realised — an 11-point premium, so options here are expensive relative to delivered movement. August IV is richer still at ~64–66% ATM, inflated by the earnings date. There is no structure whose implied move sits below a house expected move, because the house has no directional variant to express. Naked premium is therefore ruled out on the stated test, and the correct answer to "which vehicle" is none.

IV crush would hit any August structure immediately after the ~6 August print regardless of direction. Flagged, though moot given no position.

3.5 Portfolio-book context

Book config: 5% single-name max, 4.7% cash hurdle, −2%-of-book position hard stop, 25% sector-cluster cap, 0.60 pairwise-correlation disclosure threshold.

• Capital competition — SUPERSEDED. (Was: "FAILS decisively. Net E[R] −49.9% versus a risk-free 4.7%.") The cash hurdle has been retired from the framework; capital competition is now slot competition inside the strategy, and the memo does not run it. On the Criteria the memo does score, the Valuation Criteria PASSES at +25.0pp.
• Correlation: one disclosure triggered. NTRA–GH at +0.603 on 126 days exceeds the 0.60 threshold. Since GH is itself Watchlist/no-position the constraint does not bind today, but it must be enforced at conversion: NTRA and GH may not both be sized as full independent positions.
• Sector concentration: a life-science-tools/diagnostics cluster would be genuinely additive to a book dominated by AI infrastructure (NTRA mean correlation +0.167 to that cluster). Not a reason to buy at this price.
• Write-back: Watchlist entry with triggers below, in PENDING_book_and_ledger_updates.json.

3.6 Joint probability that the conversion triggers fire (v1.4.2, C6)

Per C6 this must be stated, and stated honestly enough to distinguish a real Watchlist from a No Position wearing a watchlist costume. The triggers are deliberately disjunctive where that is genuine, but the arithmetic below forced an uncomfortable admission, which is recorded rather than hidden.

→ LONG if ANY of:

JOINT (union) PROBABILITY THAT AT LEAST ONE TRIGGER FIRES: ~1 − (0.83 × 0.85 × 0.88) ≈ 38% over 18 months.

But the honest version is narrower than that number suggests, and it must be said. Triggers B and C would raise the fundamentals without closing the valuation gap — the gap is a multiple, not a forecast. Tested directly: putting the full Bull revenue path ($7.37bn FY2030E) into the Base 5.0x multiple still yields $163/share, −37% against spot. So B and C on their own do not convert this to a long; they raise the price at which it converts, from ~$130 to roughly ~$165.

Restated honestly: the only trigger that independently converts NTRA to a Long is price (A), at ~17% over 18 months. B and C are conversion-price modifiers, not independent triggers. Combining properly — P(A) plus the probability that (B or C fires and price subsequently reaches the raised ~$165 threshold) — gives an effective conversion probability of roughly 25–30% over 18 months.

That is comfortably above the ~10% "no position in a watchlist costume" floor, so the Watchlist classification is honest and is retained. But the mechanism is overwhelmingly price, not evidence, and the memo says so rather than presenting three triggers of apparently equal weight. Two genuinely different kinds of evidence are not both required here (which C6 prefers to avoid) — but nor are the three triggers truly interchangeable, and pretending otherwise would overstate the conversion odds by roughly 10 percentage points.

---

4. Catalyst Calendar

---

5. What would make me wrong

1. The multiple is doing all the work, and it is the one thing I cannot prove. At ~10.7x FY2030E sales the stock is fairly valued; the market is at ~11.2x. My case that 5.0x is right rests on a peer median and an M&A precedent — both anchors, neither a law. This is the single largest source of error in the memo.
2. Category leaders in reimbursement inflections sustain indefensible multiples for years. Natera has seven covered indications, a 70-to-1 publication lead, and a fresh NCCN recommendation. That is a real moat and it may simply keep compounding into the valuation rather than the multiple compressing.
3. The ADLT cut was absorbed without breaking ASP. I flagged reimbursement as the binding variable and then watched Q1-2026 grow ASP 19.9% through the first cut. If the CY2027 determination is also absorbed, the principal bear mechanism is gone entirely.
4. Takeout risk. Abbott paid $21bn cash for Exact Sciences four months ago. Natera is the MRD category leader with a clean balance sheet. A strategic bid would make the Bull case academic.
5. Foresight and Signatera Genome are given essentially no value in the base case, because the registry gives dates without readouts and management gives no economics. If ALPHA3 works, that is a genuine option I have priced at zero.
6. I am underwriting a name the screen rejected. NTRA sits in the second momentum decile, not the first. The selective-breadth edge hypothesis says spend underwriting effort where the empirical signals cluster; this name did not qualify, and that is a mild prior-odds negative I have accepted for diversification reasons.

---

Prepared by Phase Space Research, 2026-07-27. Options quotes, Greeks and IV: Alpaca (live, 2026-07-27). Momentum percentiles: reconstructed liquid universe, 7,230 symbols, Alpaca SIP monthly bars. Consensus: Alpha Vantage EARNINGS_ESTIMATES (cached) plus public aggregators. Trial data: ClinicalTrials.gov API v2, records opened and field-verified. Literature: PubMed E-utilities, field-tagged queries, syntax sanity-checked. Model: NTRA_Financial_Model.xlsx (verified by reading back computed cells in Excel with all other workbooks closed; balance-sheet check is 0.0 in all fourteen columns).